Novo Nordisk to Invest $4.1 Billion in North Carolina Facility, Creating 1,000 Jobs to Boost Wegovy, Ozempic Production

Jun 24, 2024, 06:29 PM

Novo Nordisk has announced a $4.1 billion investment to build a new manufacturing facility in North Carolina. The facility will focus on increasing the production of its popular weight-loss treatment Wegovy and diabetes drug Ozempic. This expansion is part of a broader strategy to bolster its U.S. manufacturing capabilities, with a total investment of $6.8 billion by 2024. The new plant in Clayton, North Carolina, is expected to create over 1,000 new jobs. The move comes amid rising discontent in the U.S. over the high cost of these drugs, with figures like Senator Bernie Sanders criticizing the price disparity between the U.S. and other countries.